SV-101 is under clinical development by Syncromune and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SV-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SV-101 is under development for non small cell lung cancer (NSCLC) and metastatic breast cancer. It is a fixed-dose combination intratumoral therapy and is being developed based on syncrovax platform technology.
Syncromune is a clinical-stage biopharmaceutical business developing a novel cancer treatment that synchronises immune processes and enhances intratumoral immunotherapy to eliminate metastatic solid tumours. The company is headquartered in Fort Lauderdale
For a complete picture of SV-101’s drug-specific PTSR and LoA scores, buy the report here.